Method for carrying therapeutic substances into cells
The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
1. A method for increasing the activity of an anti-cancer drug comprising the steps of administering to a patient in need thereof a pharmaceutical composition comprising magnetic nanoparticles having an affinity to degenerated cells, at least one pharmaceutical composition comprising an anticancer drug and at least one pharmaceutically acceptable carrier, excipient and/or solvent, wherein the magnetic nanoparticles have a positive surface charge, and comprise a coating of polycondensed aminosilane, wherein the pharmaceutical compositions comprising the magnetic nanoparticles and the at least one anti-cancer drug are administered separately, wherein the magnetic nanoparticles and the at least one anti-cancer drug are present at the same time in the patient, and wherein the increase in activity of the anti-cancer drug occurs without hyperthermia.
2. The method for increasing the activity of an anti-cancer drug according to claim 1 , further comprising administering radiation therapy.
3. The method according to claim 1 , wherein the nanoparticles comprise iron oxide, magnetite, maghemite or M(II)Fe 2 O 4 , wherein M represents Zn, Cu, Co, Ni, Cd, Ba or Mn.
4. The method according to claim 1 , wherein the at least one cancer drug is a cytostatic agent, an antiproliferative agent, an antiangiogenic agent, or a microtubule inhibitor.
5. The method according to claim 1 , wherein the at least one cancer drug is selected from the group comprising: actinomycin D, aminoglutethimide, amsacrine, anastrozole, antagonists of purine and pyrimidine bases, anthracyclines, aromatase inhibitors, asparaginase, antiestrogens, bexarotene, bleomycin, buserelin, busulfan, camptothecin derivatives, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, cytosine arabinoside, alkylating cytostatics, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin (adriamycin), doxorubicin lipo, epirubicin, estramustine, etoposide, exemestane, fludarabine, fluorouracil, folic acid antagonists, formestane, gemcitabine, goserelin, hormones and hormone antagonists, hycamtin, hydroxyurea, idarubicin, ifosfamide, imatinib, irinotecan, letrozole, leuprorelin, lomustine, melphalan, mercaptopurine, methotrexate, mitomycins, mitosis inhibitors, mitoxantrone, nimustine, oxaliplatin, pentostatin, procarbazine, tamoxifen, temozolomide, teniposide, testolactone, thiotepa, thioguanine, topoisomerase inhibitors, topotecan, treosulfan, tretinoin, triptorelin, trofosfamide, vinblastine, vincristine, vindesine, vinorelbine, cytostatically active antibiotics, somatostain, bafilomycin, 4-hydroxyoxycyclophosphamide, bendamustine, thymosin α-1, aclarubicin, fludarabine-5′-dihydrogen phosphate, hydroxycarbamide, aldesleukin, pegaspargase, adriamycin, cepharanthine, epothilone A and B, c myc antisense, b-myc antisense, betulinic acid, camptothecin, melanocyte stimulating hormone (α-MSH), lapachol, β-lapachone, podophyllotoxin, podophyllinic acid 2-ethyl hydrazide, molgramostim (rhuGM-CSF), peginterferon α-2b, lenograstim (r-HuG-CSF), filgrastim, macrogol, cephalomannine, trastuzumab, daclizumab, angiopeptin, fluroblastin, bFGF antagonists, probucol, 1,11-dimethoxyeanthin-6-one, 1-hydroxy-11-methoxycanthin-6-one, scopoletin, colchicine, staurosporine, β-estradiol, α-estradiol, estriol, estrone, ethinyl estradiol, fosfestrol, medroxyprogesterone, estradiol cypionates, estradiot benzoates, tranilast, kamebakaurin, tyrosine kinase inhibitors (tyrphostins), ciclosporin A, paclitaxel and derivatives thereof comprising 6-α-hydroxy paclitaxel, baccatin, elipticine, D-24851, colcemid, cytochalasin A-E, indanocine, nocodazole, bacitracin, vitronectin receptor antagonists, free nucleic acids, nucleic acids incorporated into virus transmitters, DNA and RNA fragments, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, antisense oligonucleotide, VEGF inhibitors, thioprotease inhibitors, interferon α, β and γ, NF-kB or Bcl-xL antisense oligonucleotides, halofuginone, nifedipine, tocopherol, tea polyphenols, epicatechin gallate, epigallocatechin gallate, boswellic acids and derivatives thereof, mutamycin, retinoic acid, natural and synthetically obtained steroids comprising bryophyllin A, inotodiol, maquiroside A, ghalakinoside, mansonine, strebloside, hippocaesculin, barringtogenol-C21-angelate 14-dehydroagrostistachin, agroskerin, agrostistachin, 17-hydroxyagrostistachin, ovatodiolids, 4,7-oxycycloanisomelic acid, baccharinoids B1, B2, B3 and B7, tubeimoside, bruceanol A, B and C, bruceantinoside C, yadanziosides N and P, isodeoxyelephantopin, tomenphantopin A and B, coronarin A, B, C and D, ursolic acid, hyptatic acid A, zeorin, iso-iridogermanal, maytenfoliol, effusantin A, excisanin A and B, longikaurin B, sculponeatin C, kamebaunin, leukamenin A and B, 13,18-dehydro-6-alpha-senecioyloxychaparrine, taxamairin A and B, regenilol, triptolide, anopterin, hydroxyanopterin, berberine, cheliburin chloride, cicutoxin, sinococuline, combrestatin A and B, cudraisoflavone A, curcumin, dihydronitidine, nitidine chloride, 12-beta-hydroxypregnadiene-3,20-dione bilobol, helenalin, indicine, indicine-N-oxide, lasiocarpine, justicidin A and B, larreatin, malloterin, mallotochromanol, isobutyrylmallotochromanol, marchantin A, maytansine, lycoridicin, margetine, pancratistatin, liriodenine, bisparthenolidine, oxoushinsunine, aristolactam-AII, deoxypsorospermin, psychorubin, ricin A, sanguinarine, manwu wheat acid, methylsorbifolin, chromones of spathelia, stizophyllin, akagerine, dihydrousambaraensine, hydroxyusambarine, strychnopentamine, strychnophylline, usambarine, usambarensine, daphnoretin, lariciresinol, methoxylariciresinol, syringaresinol, umbelliferone, afromoson, acetylvismione B, desacetylvismione A, vismione A and B.
6. The method according to claim 1 , wherein the pharmaceutical compositions are present in formulations which are suitable for injection or infusion.
7. The method of claim 1 , wherein the coating consists of polycondensed monomeric aminosilanes selected from the group of 3-aminopropyltriethoxysilane, 2-aminoethyl-3-aminopropyltrimethoxysilane, trimethoxysilyl-propyl-diethylentriamine, and N-(6-aminohexyl)-3-aminopropyltrimethoxysilane.
8. The method of claim 1 , wherein the coating consists of polycondensed N-(2-aminoethyl)-3-(trimethoxysilyl)propylamine.